Research Reflections: Sarcoma Experts Consider Emerging Evidence for Novel Combos
In our exclusive interview, Shiraj Sen, MD, PhD, and Roman Groisberg, MD, discuss key takeaways from the 2020 ASCO Virtual Scientific Program on exciting efforts being made in the field of sarcoma.
Welcome to a very special edition of OncLive® On Air! I’m your host today, Jessica Hergert.
OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
Today, we had the pleasure of speaking with Shiraj Sen, MD, PhD, and Roman Groisberg, MD, to discuss key takeaways from the 2020 ASCO Virtual Scientific Program on exciting efforts being made in the field of sarcoma.
In our exclusive interview, Dr. Sen, associate director of Drug Development at Sarah Cannon Research Institute, and Dr. Groisberg, a medical oncologist at Rutgers Cancer Institute, highlighted research evaluating checkpoint inhibitors and combination chemotherapy regimens in the evolving sarcoma treatment paradigm.
